Considering AnxA1 is a strong candidate for predictor of disease remission due to therapies on IBDs and AnxA1 expression levels tend to vary greatly in IBD patients, such information might aid elucidating why clinical trials investigating PPARγ ligands on IBDs tend to fail (Lewis et al., 2001; Lewis et al., 2008). This evidence concerns the gene ANXA1 and inflammatory bowel disease.